Hypnotic suggestibility as a moderator of treatment response in mild to moderate depression: an exploratory secondary analysis - Top-Institutions - MDSpire

Hypnotic suggestibility as a moderator of treatment response in mild to moderate depression: an exploratory secondary analysis

  • By

  • Julia Siewert

  • Benno Brinkhaus

  • Tatjana Tissen-Diabaté

  • Michael Teut

  • Nicolas Volz

  • July 2, 2026

  • 0 min

Share

Top Institutions in Psychiatry

Brief introduction explaining scope and methodology.

  • #1

    Harvard University
    Harvard University

    Cambridge, MA

    Key Differentiators

    • Psychiatry

  • #2

    Jena University Hospital
    Jena University Hospital

    Jena, Germany

    Key Differentiators

    • Psychiatry

  • #3

    Hangzhou Seventh People’s Hospital
    Hangzhou Seventh People’s Hospital

    Hangzhou, China

    Key Differentiators

    • Psychiatry

  • #4

    First Affiliated Hospital of Jinan University
    First Affiliated Hospital of Jinan University

    Guangzhou, China

    Key Differentiators

    • Psychiatry

  • #5

    Umeå University Hospital
    Umeå University Hospital

    Umeå, Sweden

    Key Differentiators

    • Psychiatry

Original Source(s)

Hypnotic suggestibility as a moderator of treatment response in mild to moderate depression: an exploratory secondary analysis

  • by Julia Siewert, Benno Brinkhaus, Tatjana Tissen-Diabaté, Michael Teut, Nicolas Volz

  • July 2, 2026

Related Content

Side Effects: The Hidden Variable

The partner in the next room, the hormone in the blister pack, the cat on the couch, the minute-long chair stand. Several new studies suggest the factor shaping outcomes may be the one clinicians aren’t routinely measuring.

In vivo probing of purinergic P2X7 as a potential biomarker for suicide risk: a hypothesis

Blindness Linked to Higher Loneliness Scores

Analysis of more than 61,000 patients found higher odds of elevated loneliness scores among those reporting blindness and those with diabetic retinopathy, but not among patients with glaucoma or age-related macular degeneration.